NCT05414669View on ClinicalTrials.gov

Allopurinol Effect on MDA,NO,KIM-1 Urine Levels, RI and Renal Elastography in Kidney Stone Patients Post ESWL

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 6, 2020

Primary Completion Date

March 1, 2021

Study Completion Date

April 20, 2021

Conditions
Kidney Calculi
Interventions
DRUG

Allopurinol Tablet 300 mg

Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.

DRUG

Control Group

Placebo was given orally for a total of 3 days, beginning a day before ESWL.

Trial Locations (1)

80114

Sanglah General Hospital, Denpasar

All Listed Sponsors
lead

Sanglah General Hospital

OTHER

NCT05414669 - Allopurinol Effect on MDA,NO,KIM-1 Urine Levels, RI and Renal Elastography in Kidney Stone Patients Post ESWL | Biotech Hunter | Biotech Hunter